The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Pivotal safety and efficacy results for liso-cel in R/R B-NHL
Jeremy Abramson, MD, Massachusetts General Hospital Cancer Center, Boston, MA, discusses the pivotal safety and efficacy results from the TRANSCEND-NHL-001 study (NCT02631044). This is a phase I study evaluating lisocabtagene maraleucel (liso-cel), an investigational, anti-CD19 CAR T-cell product, in adult patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). Dr Abramson highlights the very encouraging results, including durable clinical activity and a favorable safety profile. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
